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1. Introduction 
This chapter focuses on the gene therapy advances made in relation to Duchenne muscular 
dystrophy and discusses principles and perspectives of strategies currently being 
developed. The chapter explains the genetic mutations that cause Duchenne muscular 
dystrophy (DMD) and Becker muscular dystrophy (BMD) and the differences between the 
two are discussed in relation to disease severity. The histopathological features of DMD are 
explained and discussed in the context of available animal models for DMD. There are 
various genetic therapeutic options available for the treatment of DMD, and the progress of 
each therapeutic approach is promising. A number of specific areas for the treatment of 
DMD are comprehensively presented, alongside in-depth description of the genetic biology 
of muscular dystrophy.  
2. Muscular dystrophies 
Muscle-related proteins build the structural network of muscle, and disruption of this link 
can cause muscle wasting and progression of numerous types of muscular dystrophy. 
Muscular dystrophies are a heterogeneous group of genetic disorders caused by different 
forms of mutations in various genes related to muscles.  
2.1 Duchenne and Becker muscular dystrophy  
The most common forms of muscular dystrophy are Duchenne and Becker muscular 
dystrophy (DMD, BMD). DMD and BMD are X-linked recessive muscle-wasting disorders 
affecting the skeletal musculature, resulting from mutations in the gene encoding 
dystrophin, which is a cytoskeletal protein in muscle fibres. Dystrophin protein interacts 
with the intracellular and extracellular dystrophin associated protein (DAP) complexes. 
Mutations in dystrophin gene can cause severe muscular wasting. 
Different mutation types in exon/ intron regions of dystrophin gene or promoters causes 
various forms of dystrophinopathies (Giliberto et al., 2004). Dystrophin deficiency leads to 
disruption of the dystrophin associated protein (DAP) complexes, as do mutations in DAP 
genes in other forms of congenital and autosomal muscular dystrophy.  
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DMD affects 1:3500 newborn males worldwide, and patients exhibit severe, progressive 
muscle weakening. From about the age of 4 years, youngsters affected by DMD suffer bouts 
of recurrent damage and regeneration of skeletal muscle, leading eventually to muscle 
wasting and weakness, wheelchair-dependence, and life-threatening cardiac and respiratory 
complications. This debilitating disease is associated with loss of dystrophin expression 
caused generally by frameshift gene deletions and duplications, or by nonsense point 
mutations in the dystrophin gene.  
In BMD, muscle pathology is generally milder than in DMD, and can even be virtually 
asymptomatic. The milder BMD phenotype is caused by the continued expression of 
truncated but partially functional dystrophin proteins in the affected muscles. This 
phenotype commonly arises due to mutational events which delete central rod domain 
elements, but nevertheless maintain the open reading frame upstream and downstream of 
the mutation boundaries. Thus different mutation types across exon/intron regions of the 
dystrophin gene can give rise to either DMD or BMD, depending upon the deletion 
boundaries.  
BMD can be related to large in-frame deletions, including examples where up to 46% of the 
dystrophin-coding sequence has been deleted (Acsadi et al., 1991). Despite the large gene 
deletion, BMD patients have a mild phenotype due to partial expression of an internally-
deleted but highly functional dystrophin protein. Clinical phenotype of BMD pathology is 
discriminated by mild, intermediate and severe types resulting from different exon deletions 
(Chao et al., 1996). Around 20% of normal dystrophin expression is seen as the milder BMD 
phenotype (Beggs et al., 1991).  
2.1.1 Histopathological features of DMD  
Clinical symptoms of DMD become apparent in patients of three to five years of age, while 
fetal DMD muscle is histologically normal (Biggar, 2006). The lack of dystrophin causes 
DAP dissociation, followed by disruption of the transmembrane link between extracellular 
matrix and the cytoskeleton. This causes severe muscle damage along with progressive 
fibrosis and muscle fibre loss. Lack of dystrophin in DMD muscles is believed to 
compromise the integrity of the sarcolemma, leading to calcium influx and myofibre 
necrosis. Central nucleation and uneven size of fibres are observed in early stages of 
dystrophinopathies due to the muscle necrosis followed by muscle degeneration and 
regeneration (Bell et al., 1968, Bradley et al., 1972). In dystrophin-negative muscles, fibres are 
lost (necrosed) and degeneration of the fibres proceeds, and they are eventually replaced by 
adipose and fibrous connective tissue, followed by atrophy (Figure 1) (Blake et al., 2002). 
In addition, an increased number of proteasomes is found in necrotic and regenerative 
muscles in DMD, leading to muscle fibre degradation (Kumamoto et al., 2000). Muscle 
membrane becomes abnormally permeable, leading to fragility and leakiness of the muscle 
cells. The muscle weakness results in loss of independent ambulation, usually by the age of 
12 (Emery, 2001). DMD patients eventually die from intercostal muscle weakness and 
respiratory failure in their early twenties (Emery, 2001). DMD patients also develop cardiac 
dysfunction with cardiomyopathy, resulting in heart failure and progressive dilated 
cardiomyopathy (Emery, 2001).  
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There is also evidence that dystrophin deficiency is associated with aberrant signal 
transduction from influx of divalent cations such as calcium due to abnormal membrane 
permeability in DMD muscle cells (Ruegg et al., 2002). Abnormality of calcium homeostasis 
is found due to structural defects in the ryanodine receptor (RyR) 1, calcium release channel in 
the sarcoplasmic reticulum, leading to increase of intracellular Ca2+ in the dystrophic 
muscles (Bellinger et al., 2009). Increased intracellular Ca2+ can activate calpain, which has a 
role in proteolysis and increases reactive oxygen species (ROS). Calpain cleaves intracellular 
proteins including titin, nebulin, desmin, troponin, tropomyosin and many kinases and 
signalling molecules and it increases protein breakdown (Allen et al., 2005). This can cause 
protein and membrane damage (Whitehead et al., 2006).  
 
Normal muscle shows even size/diameter distribution of muscle fibres with dystrophin expression 
localised at the sarcolemma membrane. Lack of dystrophin protein expression in DMD causes muscle 
damage, which is accelerated by eccentric contraction of the muscle membrane. Eventually, muscle 
fibres are lost (necrosed) and replaced by adipose and fibrous connective tissue.  
Fig. 1. Dystrophin immunohistochemistry in normal (left panel) and DMD muscle (right 
panel).  
Damaged muscle membranes are demonstrated by staining with extracellulary applied 
labelled endogenous extracellular proteins such as albumin, immunoglobulin (Ig) G and 
IgM (Blake et al., 2002). The already permeable membrane in DMD becomes more 
permeable after mechanical stress or electric stimulation. Cardiomyopathies occur as a 
result of cardiac muscle damage in DMD. Myocardium is replaced by fat and connective 
tissue in dystrophinopathies. Clinical symptoms of cardiomyopathies appear after 10 
years of age in DMD, and are present in all patients over 18 years (Finsterer et al, 2003). It 
has been currently reported that 20% of BMD and 50% of DMD patients eventually die 
due to cardiac failure (Finsterer et al., 2003). In the early stages of DMD, focal myofibre 
necrosis initially leads to muscle stem cell activity and tissue regeneration, via activation 
of so-called satellite cells. As the disease progresses, however, the capacity to regenerate 
muscle becomes impaired owing to depletion of stem cells and fibrosis of tissues, leading 
finally to severe muscle wasting. This leads to inflammation of DMD muscles, as a result 
of inflammatory cells such as CD4 and CD8, followed by muscle necrosis (Blake et al., 
2002). 
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Creatine kinase (CK) level is one of the indicators for DMD pathology. CK level in DMD in 
affected boys is elevated at birth, to 50 to 100 times the novel level, and gradually declines in 
the late stages of the disease (Emery, 2001).  
2.1.2 Animal models of DMD  
The development of a treatment for any disease relies on the use of appropriate animal 
models to test the efficacy, deliverability, dosing regimen and toxicology in vivo having 
established the therapeutic potential in vitro. 
2.1.2.1 Dystrophin deficient mdx model 
The mdx mouse originates from the C57BL/10 colony and does not express the dystrophin 
protein due to a nonsense mutation (CAA to TAA) in exon 23 of the dystrophin gene 
(Sicinski et al., 1989). It shows similar pathological symptoms to human DMD patients. 
However the pathology of mdx mice is less severe compared to the human disease, because 
of effective regeneration of damaged muscles, which has not been observed in human DMD 
patients (Turk et al., 2005). In mdx mice, the event of degeneration/regeneration is ongoing 
throughout the life of the animal but peaks between the ages of 3-8 weeks (Tanabe et al., 
1986). It has been demonstrated that the mdx mouse has a reduced life span and progressive 
dystrophic muscle histopathology compared to the wild-type C57BL/10 mouse 
(Chamberlain et al., 2007). Moreover, aged mdx mice are susceptible to muscle tumours, 
similar to human alveolar rhabdomyosarcoma (Chamberlain et al., 2007). Inflammatory cells 
such as CD4 and CD8 are found in dystrophin-deficient muscles followed by muscle 
necrosis, peaking at 4-8 weeks old of mdx mice (Blake et al., 2002). In dystrophic mdx mice, 
elevated CK level was also found in the serum (Bulfield et al., 1984).  
2.1.2.2 Canine muscular dystrophy model 
The golden retriever muscular dystrophy (GRMD) dog was the first characterized canine 
model of DMD (Cooper et al., 1988, Kornegay et al., 1988, Valentine et al., 1992). It has been 
reported that GRMD dogs eventually die due to cardiomyopathy. GRMD has been identified 
as complete dystrophin deficiency with higher genotypic/phenotypic similarity to human 
DMD disease than that of the mdx mouse model. Complete loss of dystrophin is the result of a 
nonsense mutation in the 3’ consensus splice site of intron 6, leading to skipping of exon 7 and 
alteration of the reading frame in exon 8, thereby inducing clinical symptoms similar to human 
DMD (Chamberlain et al., 2007). The Beagle-based CXMD canine model was also identified as 
a DMD model in Japan (Shimatsu et al., 2003). It has been reported that limb muscle 
abnormality appear after 2 months of age and the dogs eventually die mainly due to 
cardiomyopathy (Valentine et al., 1988). CXMD dog models show longer life span due to slower 
progression of muscle wasting compared to GRMD dogs (Willmann et al., 2009). Progress of 
cardiomyopathy in the CXMD dog is also milder than in GRMD (Yugeta et al., 2006).  
2.1.2.3 Hypertrophic Feline muscular dystrophy model 
Hypertrophic feline muscular dystrophy (HFMD) is exhibited in cats (Blake et al., 2002). The 
creatine kinase (CK) level is increased at the age of 4-5 weeks and development of severe 
muscle hypertrophy is shown resulting in muscle necrosis and regeneration. However, it is 
not considered to be a good model for human DMD since it does not induce muscle fibrosis 
and muscle wasting (Gaschen et al., 1992).  
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2.2 Other muscular dystrophies 
2.2.1 Muscular disorders caused by mutations in membrane proteins 
Mutations in integrin have been shown to cause congenital muscular dystrophies. Integrin, 
membrane protein, binds to laminin. Caveloin-3, which is localised to muscle cell membrane 
interacts with -dystroglycan and mutations in Caveloin-3 cause the autosomal dominant 
form of Limb Girdle muscular dystrophy 1C (LGMD1C), rippling muscle disease and hyper 
CKemia (Betz et al., 2001, Carbone et al., 2000).  
2.2.2 Muscular disorders caused by mutations in extracellular matrix proteins 
Mutations in laminin -2, one of the extracellular matrix proteins, can give rise to congenital 
muscular dystrophy 1A (MDC1A) (Helbling-Leclerc et al., 1995).  and  form of 
dystroglycan can interact with laminin and dystrophin, respectively. Mutations in -
dystroglycan have been reported in the muscle-eye-brain disease, Walker-Warburg 
syndrome (WWS) and a type of congenital MD (Longman et al., 2003). In mice, mutations in 
the dystroglycan gene can be embryonically lethal (Williamson et al., 1997). Disruption to 
the transmembrane related sarcoglycan-sarcospan complex leads to various types of LGMD. 
Sarcoglycan interacts with biglycan, which also binds to -dystroglycan and as well as to 
collagen VI. Mutation in collagen VI gives rise to Ullrich syndrome and Bethlem myopathy 
(Camacho Vanegas et al., 2001).  
2.2.3 Muscular disorders caused by mutations in intracellular proteins 
Mutation in calpain 3, which is a calcium-dependent protease, gives rise to LGMD 2A. 
Mutations in several sarcomeric proteins lead to LGMD 2. Heterogeneous chromosomal 
mutations result in LGMD. There are two types of LGMD called type 1 and type 2, which 
have autosomal dominant or autosomal recessive mutations, respectively. The symptoms 
are not as severe as DMD or BMD, but weakness of proximal limb and trunk muscles is 
exhibited (Lovering et al., 2005). Mutations in syntrophin and dystrobrevin display mild 
forms of skeletal and cardiac muscle disease.  
2.2.4 Muscular disorders caused by mutations in nuclear proteins 
Laminopathies are caused by mutations in the LMNA gene, which encodes the inner 
nuclear envelope proteins lamin A and C, which interact with several proteins in the 
nucleus and inner nuclear membrane (Worman et al., 2000). Emery-Dreifuss muscular 
dystrophy (EDMD) has been identified due to a mutation in LMNA gene encoding A-type 
lamin, or in emerin gene encoding nuclear protein (Bione et al., 1994). Clinical symptoms are 
related to humero-peroneal weakness and dilated cardiomyopathy with conduction defects 
(Emery, 2000). Mutations in LMNA gene cause cardiomyocyte nuclear envelope 
abnormalities, leading to dilated cardiomyopathy in human patients (Gupta et al., 2010) and 
LGMD 1B (Muchir et al., 2000). 
3. Pre-clinical & clinical approaches for DMD  
Several pre-clinical research regimes have displayed that DMD pathology can be improved by 
functional expression of mini-or micro-dystrophin gene variants (Deconinck et al., 1996). 
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3.1 Recombinant adeno-associated virus vector (rAAV) mediated gene therapy 
Gene therapy for DMD aims to compensate for dystrophin loss-of-function by different gene 
transfer approaches. To prevent muscle degeneration, around 30% of normal levels of 
dystrophin protein is likely to be required (Neri et al., 2007). Transfer of recombinant genes 
encoding full-length (~11 kb), mini- (>5 kb) or micro- (<5 kb) dystrophin recombinant gene 
into DMD-affected muscle is one of the proposed therapies to induce dystrophin protein 
expression. A Phase I clinical trial has been completed in which a eukaryotic expression 
plasmid encoding full length human dystrophin was injected directly into the muscles of 
DMD patients (Fardeau et al., 2005). 
 
The mdx mice treated with AAV-mediated microdystrophin gene transfer (left-hand panel), or PMO 
antisense-induced skipping of the mutant exon 23 (right-hand panel) showed dystrophin expression at 
the sarcolemma in the TA muscle of mdx mouse.  
Fig. 2. Dystrophin immunofluorescence staining of muscle.  
Dystrophin expression at low levels was shown in all patients without any safety concerns and 
notably without a detectable immune response to dystrophin. A Phase I/II study is currently 
in preparation to evaluate this non-viral plasmid-mediated gene therapy using vascular 
systemic routes of administration to target multiple muscle groups. However, even with the 
aid of more sophisticated delivery strategies such as electrotransfer or even with enhanced 
vector configurations such as minicircles and episomes, effective plasmid gene therapy for 
DMD still has major hurdles to overcome to reach the gene-transfer efficiencies required for 
effectiveness. Therefore a range of replication-defective viral vectors have been evaluated as 
attractive delivery systems to mediated dystrophin gene transfer and DMD gene therapy.  
In particular, gene transfer into the nuclei of muscle fibres using vectors based on adeno-
associated virus (AAV) is one of the most promising delivery approaches for the therapy of 
muscle disease. AAV is a single-stranded non-pathogenic virus, and derived vectors of 
various serotypes can efficiently transduce, not only by local muscle injection, but also, 
notably, by vascular systemic delivery to widespread muscle groups and the heart. The 
tropism of various AAV vector serotypes for differentiated post-mitotic muscle tissues can 
be very high, reaching >90%. 
However, there is a hurdle to AAV-mediated DMD gene therapy, since the full dystrophin 
coding sequence spans 14 kb mRNA with an open reading frame of >11 kb, and the 
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packaging capacity of AAV virus vectors is generally thought to be <5 kb. Thus, on the basis 
of an understanding of the genotype-phenotype correlates in DMD and BMD, and based on 
structural knowledge of the dystrophin protein, recombinant dystrophin cDNAs have been 
engineered to produce, partially deleted, but highly functional microdystrophin products in 
both mdx mouse and CXMD dog models (Athanasopoulos et al., 2004, Foster et al., 2008, 
Koo et al., 2011). These genes can be packaged successfully inside AAV vector particles and 
can be delivered at high efficiency to skeletal muscles to rescue the dystrophin-deficient 
phenotype in animal models of DMD (Figure 2, left hand panel). 
The life cycle of AAV vectors results in delayed expression, and it takes several weeks for 
full transcriptional activity to be established (Ferrari et al., 1996). Recently, self-complementary 
AAV (scAAV) vectors have been developed for fast expression by bypassing rate-limiting, 
second-strand DNA synthesis (McCarty 2008). However, scAAV can only retain smaller 
transgene cassettes compared to single stranded AAV (ssAAV). Moreover, high titres of 
rAAV are required for systemic delivery (Gregorevic et al., 2004). 
AAV-mediated gene therapy has attractive characteristics and some advantages over other 
vector systems for several reasons. AAV vector particles are very stable and resistant to 
significant variation in pH and temperature. AAV vectors have an ability of long-term 
transgene expression without significant immune response. Therefore, it is a promising 
delivery vehicle for the transfer of therapeutic genes for the treatment of inherited diseases. 
Recombinant AAV-mediated gene therapy has been approved for use in over 40 clinical 
trials for various genetic diseases (Mueller at al., 2008). In order to generate recombinant 
AAV vector for the transfer of therapeutic genes, the genes for the capsid proteins and 
replication proteins are replaced with the gene of interest and packaged by ITRs. A Phase I 
clinical trial involving local intramuscular injection of AAV vectors to transfer a 
microdystrophin variant in DMD patients has been conducted by the groups of Mendel, 
Xiao and Samulski, in collaboration with Asklepios Biopharmaceuticals. However, 
microdystrophin expression was only detected in two of six patients treated at very low 
levels and two patients exhibited pre-existing dystrophin specific T cells (Mendell et al., 
2010). Further work to enhance the expression and functionality of microdystrophins is still 
required due to reported failure of certain microdystrophin variants to protect muscle 
integrity in larger animal models (Sampaolesi et al., 2006). 
3.2 Adenovirus-mediated gene therapy  
Adenovirus is another vehicle which can be used to transfer dystrophin genes towards DMD 
mediated gene delivery applications. Due to the large gene capacity of the adenoviruses, large 
cDNA cassettes, up to 7 kb for E1/E3 deleted Ad vectors, can be transferred into the muscles. 
However, adenovirus is highly immunogenic and this may cause loss of transgene expression 
through immune responses. Moreover, the packaging capacity is still too small for the transfer 
of full length dystrophin (approximately 11 kb cDNA). To increase the packaging capacity of 
the viruses, helper dependent adenovirus vectors have been developed (Fisher et al., 1996). 
These vectors contain only ITR and capsid genes and so increase the packaging genome 
capacity of adenoviruses up to 36 kb; they are also less immunogenic compared to E1 gene-
deleted adenovirus due to the lack of viral genes. Adenovirus-mediated full length 
dystrophin cDNAs have been successfully transferred to mdx mice leading to muscle 
improvement (Dudley et al., 2004). Cell transplantation of genetically corrected 
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mesenchymal cells (MSCs) by adenovirus carrying microdystrophin gene was attempted and 
showed successful dystrophin expression in MSCs in mdx mice (Xiong et al., 2007).  
3.3 Modulation of exon-splicing patterns with antisense oligonucleotides 
About 70% of DMD and BMD cases are caused by genomic deletions, leading to the loss of 
one or more exons (Aartsma-Rus et al., 2006). Frameshift deletions, which juxtapose out-of-
phase exons in the dystrophin gene, cause complete loss of expression of dystrophin and a 
DMD phenotype, whereas juxtaposition of in-phase exons leads to the milder BMD. 
Inhibition of the splicing of specific exons, by so called exon skipping, using antisense 
oligonucleotides (AONs) can induce exclusion of targeted exons and skipping of frame-shift 
exons, leading to restoration of disrupted reading frames and expression of BMD-type 
dystrophin molecules (Figure 2, right hand panel). AONs are designed to hybridize to 
consensus exon recognition or exonic splicing enhancer (ESE) sequences on dystrophin pre-
mRNA, and antisense-induced exon skipping is thought to occur by interfering with 
binding of serine/arginine-rich (SR) proteins which play crucial roles in recruiting the 
splicing machinery (Figure 3). 
AON-induced exon skipping to restore functional but truncated dystrophin protein 
expression has previously been demonstrated in animal models of DMD both in vitro 
(Graham et al., 2004) and in vivo (Yokota et al., 2009), and in DMD patient cells in vitro in 
culture (van Deutekom et al., 2001), and in DMD muscle explants (Arechavala-Gomeza et 
al., 2007). On the basis of these pre-clinical studies, a number of patient trials, phase I and 
more recently phase 2, have been undertaken. In the first of these, four DMD patients 
carrying appropriate deletions received a single intramuscular injection of a high dose of an 
AON with a 2'O-methylphosphorothioate backbone (PRO051), which targets exon 51. Each 
patient showed specific exon 51 skipping, myofibre expression of dystrophin protein, which 
was detectable at 3 to 12% of normal levels four weeks after injection. No clinically adverse 
events were detected (van Deutekom et al., 2007). In the second trial, the AON AVI-4658, 
which has a phosphorodiamidate morpholino (PMO) backbone and targets a slightly 
different intraexonic sequence (+68+95) of exon 51, has been injected intramuscularly in a 
dose-escalating trial into nine DMD boys. At the higher doses, this PMO AON produced 
good levels of local dystrophin protein production in treated muscles; the intensity of 
dystrophin staining was up to 42% of that seen in healthy muscle. The treatment had no 
adverse effects (Kinali et al., 2009). The clinical evaluation has been extended to 12 week 
systemic delivery of both exon 51 AONs and results have very recently been reported. Both 
chemistries showed no adverse effects and dose-dependent restoration of dystrophin 
production was clearly seen; functionality of this expressed dystrophin protein was 
established by the detection of other dystrophin-associated proteins at the sarcolemma (for 
AVI-4658), and by a modest but not statistically significant improvement in the patient six 
minute walk test after 12 weeks of extended treatment (for PRO051) (Goemans et al., 2011). 
On the basis of results seen in the mdx model using various dosing regimen over extended 
periods (Malerba et al., 2011), further clinical studies are required. 
PMOs and 2’OMe AONs both have excellent safety profiles (van Deutekom et al., 2007), but 
PMOs have certain advantages over 2’OMe AONs. They give more sustained, consistent exon 
skipping in the animal mdx model in vivo (Heemskerk et al., 2009), and in human muscle 
explants (Arechavala-Gomeza et al., 2007). PMOs can be conjugated to cell-penetrating 
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peptides (PPMO) that improve their deliverability and hence efficacy dramatically (Moulton et 
al., 2007, Yin et al., 2010).  
The drug company AVI BioPharma has performed preclinical studies with AVI-5038 in 
collaboration with the charity Charley’s fund. AVI-5038 is a PPMO targeted to skip exon 50 of 
the dystrophin gene. Repeated weekly intravenous bolus injection over four weeks at a low 
dose of this conjugated PMO was shown to be well-tolerated; however higher doses 
administered weekly for 12 weeks showed significant toxicological effects, particularly in 
relation to the kidney. As yet this problem has not been resolved, and an unconjugated version 
of the same PMO (AVI-4038) is being developed for clinical trial. There are a number of 
alternative peptide conjugates that show promise as enhancers of deliverability and are 
undergoing rapid pre-clinical development (Yin et al., 2010). The next planned UK phase I trial 
by the MDEX consortium will involve conjugation of a PPMO developed for the targeted 
skipping of exon 53 (Popplewell et al., 2010) and is supported by a Wellcome Trust. The Dutch 
are currently performing a phase I trial using a 2’OMe PS AON for the targeted skipping of 
exon 45. However, it should be noted that only 8%, 4%, 13% or 18% of DMD patient mutations 
should be convertible into a BMD phenotype by a single AON exon 45, 50, 51 or 53 skipping, 
respectively. Personalized molecular medicine for each skippable DMD deletion is necessary 
and this would require the optimization and clinical trial workup of many specific AONs. It 
has been suggested that multi-exon skipping, using cocktails of AONs or chemically linked 
AONs, around deletion hotspots (eg exons 45-55) may have the potential to treat 
approximately 65% of DMD patients (Adams et al., 2007). Such a strategy has been shown to 
work in mdx mice, but this has not yet been achieved in DMD patient cells.  
 
Fig. 3. AONs mediated exon skipping for Duchenne muscular dystrophy.  
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This gene therapy restores the open reading frame of the disrupted reading frame to allow 
synthesis of shortened dystrophin. The in-frame transcript contains both the N- and C- 
terminal domains of dystrophin and is partially functional since these domains have 
important signalling functions between the extracellular matrix and cytoskeleton. The in-
frame transcript of dystrophin produced by AONs exon skipping ameliorates the severe 
muscle damage seen in mdx mice. 
There are further obstacles to be overcome for AON-induced exon skipping to be a viable 
gene therapy for DMD. The cost implications may end up being prohibitive for many 
patients; since AONs are rapidly cleared from the circulation, regular administrations of 
high doses of AON would be required for therapeutic effect. Secondly, although 
deliverability, particularly to the heart, is enhanced with the use of conjugated PMOs, their 
potential toxicological and immunogenic problems need to be addressed. Lastly, the need 
for personalized medicine will require the completion of many expensive, lengthy clinical 
trials of many AONs.  
3.4 Cell transplantation therapy 
Cell-based gene therapy is another promising approach to treat DMD. Transplantation of 
genetically modified adult muscle stem cells or healthy wild-type donor cells has great 
potential to regenerate skeletal muscle cell tissues. For stem cell therapy, adult muscle stem 
cells, including mesoangioblasts, MDSCs (muscle derived stem cells), adult progenitor cells, 
AC133+ cells, bone marrow-derived stem cells and side population (SP) cells can be isolated 
from either muscle biopsies or blood (Farini et al., 2009). Isolated stem cells can be 
transduced in vitro by retroviral or lentiviral vectors to permanently introduce the micro- or 
mini-dystrophin gene. Retrovirus or lentiviral genome can integrate into the infected cell 
genome subsequent to cell divisions. Therefore this is a promising vehicle for the correction 
of muscle satellite stem cells. These genetically modified cells or healthy wild-type donor 
cells are expanded ex vivo and subsequently injected systemically to traffic and target to 
muscles. If taken from the patient themselves, transplantation of autologous gene-modified 
stem cells has the advantage to potentially avoid adverse immune responses and cell 
rejection.  
Intramuscular myoblast transplantation in DMD yields dystrophin-positive myofibres at 
levels of 20-30% up to 18 months after transplantation (Skuk et al., 2007). However, 
intramuscular myoblasts transfer faces potential limitations in terms of cell migration, lack 
of systemic whole-body delivery and poor cell survival. There are currently two approaches 
using a cell transfer platform for systemic delivery of regenerative cell transplants to skeletal 
musculature, namely the mesoangioblast and the CD133+ stem cell systems. Following 
lentiviral vector-mediated gene transfer, dystrophin-expressing fibres have been shown in 
dystrophic dogs after transplantation of genetically modified mesoangioblasts which are 
vessel-associated progenitor cells. In this study, transplantation efficiency seemed higher in 
recipients treated with wild-type donor mesoangioblasts compared with autologous gene–
modified mesoangioblasts (Sampaolesi et al., 2006), but uncontrolled effects of immune 
suppression regimes may complicate the interpretation. Even so, a clinical trial of 
mesoangioblast cells therapy for DMD using tissue –matched wild-type donor cells has been 
tried (Cossu et al., 2007). CD133+ stem cell therapy is another promising approach 
introduced recently, making systemic delivery and correction possible. CD133+ cells can be 
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isolated from peripheral blood or skeletal muscle tissue, and differentiated into muscle, 
hematopoietic and endothelial cell lineages (Peault et al., 2007). A Phase I clinical trial of 
autologous transplantation of CD133+ stem cells in DMD boys has shown increased potential 
to contribute to muscle repair without adverse effects (Torrente et al., 2007). However, 
interaction between satellite cells and stem cells still remains largely unknown to date. 
Detailed understanding of the biological mechanism of interaction and structure/function 
relationship between muscle and the multiple components of these therapies can aid the 
search for an effective cure for DMD and other muscle diseases in the immediate future.  
3.5 Muscle augmentation 
Neuromuscular disorders, sarcopenia, cancer, AIDS and general insufficient energy intake 
can decrease the muscle mass with consequent irreversible loss of body weight (Matsakas et 
al., 2009). Several genetic based strategies have been tried to manipulate expression of 
specific molecules involved in muscle growth to counteract this muscle loss. One of the most 
promising approaches is based on the inactivation of the biological activity of myostatin or 
its receptor, Activin type 2b (ActRIIb). This strategy has a therapeutic potential to treat DMD 
by inhibiting the severe muscle loss.  
3.5.1 Inactivation of Myostatin  
Myostatin (named also GDF-8) is a member of transforming growth factor β superfamily of 
growth factors. Myostatin is initially synthesized as inactive pre-propeptide and it is cleaved 
to produce a smaller peptide (Thies et al., 2001, Hill et al., 2002) that is biologically active 
only after further post-translational processing including the formation of a homodimeric 
protein. Some animals carrying different types of mutations that inactive the functionality of 
myostatin, present a significant increase in muscle mass (Tobin et al., 2005). In myostatin 
mutant mice, individual muscles weigh twice as much compared to wild type mice 
(McPherron et al., 1997) due to hyperplasia and hypertrophy. Other identified mutations of 
myostatin gene have led to new breeds of cattle (e.g. Belgian blue or Piedmontese 
(McPherron et al., 1997) and dogs (Mosher et al., 2007). These findings have made myostatin 
the first target of a genetic approach to silence the gene expression and induce increase in 
muscle mass as therapeutic treatment for muscle wasting diseases. Indeed, even if the 
biodistribution of myostatin has not been conclusively clarified, the fact that skeletal muscle 
is the tissue with the highest expression of myostatin (Sharma et al., 1999, McPherron et al., 
1997) means this protein is an appealing target for muscle augmentation strategies. Several 
strategies aiming to knock down myostatin to induce muscle mass augmentation have been 
preclinically tested: adeno-associated viral vectors have been used to deliver myostatin 
propeptide and so inactivate the growth factor by making it unavailable for binding its 
receptor (Foster et al., 2009; Matsakas et al., 2009). Follistatin-related gene (FLRG) and 
growth and differentiation factor association protein (GASP-1) are both able to bind to the 
homodimeric protein myostatin and inhibit its functionality even if the effect is less 
pronunciated compared to the use of a pro-peptide coded by viral vectors (Thies et al., 2001, 
Hill et al., 2002). Other strategies to inactivate myostatin are the use of antibodies raised 
against this growth factor in order to make it unavailable to the receptor. The antibodies 
JA16 or MYO-029 have been preclinically tested with the latter being also used for a clinical 
trial in humans where it demonstrated good tolerability and safety (Hill et al., 2002). A 
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recent strategy to knock down myostatin is based on the use of antisense oligonucleotides to 
bind the pre-mRNA, skip the second exon of myostatin and induce the formation of an out 
of frame transcript unable of being translated in a functional protein (Kang et al., 2011). The 
systemic administration of antisense oligonucleotide in mouse showed encouraging results 
even if the effect was less pronunciated compared to the overexpression of pro-peptide or 
the myostatin specific antibody administration.  
3.5.2 Inactivation of Activin receptor IIb 
A second target used to significantly decrease the biological effect of myostatin is to 
inactivate its binding to the receptor, activin receptor IIb (ActRIIb). The overexpression of 
myostatin antagonist follistatin, which binds ActRIIb sterically, prevents the binding of 
myostatin (Rodino-Klapac et al., 2009) and induces an increase in muscle mass. Another 
study explored the possibility of inhibiting myostatin by using RNAi against ActRIIb and 
restore quasi dystrophin by AAV-U7 mediated exon skipping in a mouse model of muscular 
dystrophy (Dumonceaux et al., 2010). Recently in the same animal model the use of soluble 
ligands of ActRIIb as peptides, including the extracellular portion of the ActRIIb fused to the 
Fc portion of murine IgG (sActRIIb), has been shown to improve skeletal muscle mass and 
functional strength (Pistilli et al., 2011).  
3.6 Drug-induced read-through of nonsense mutations 
Although most DMD cases are caused by large intragenic deletions, 10-15% of DMD 
mutations are nonsense point mutations which cause premature termination codons (PTCs) 
in the dystrophin mRNA. PTC 124 is a drug designed to induce translational read through 
of PTCs, thus inducing expression of dystrophin and reducing nonsense-mediated mRNA 
decay. Because of the mechanistically structural differences between PTCs and natural stop 
codons, PTC 124 appears to preferentially recognize mutant nonsense codons without 
interfering strongly with native termination codons of unrelated genes. PTC 124 has been 
proven to enhance dystrophin expression in both primary DMD muscle cells and animal 
models (Welch et al., 2007). A Phase 2b clinical trial in subjects with nonsense-mutation-
mediated DMD/BMD has been completed. Unfortunately, PTC 124 did not render any 
improvement in the six minute walk distance. 
4. Conclusion 
Preclinical and clinical genetic and cell-based therapy trials are currently progressing 
rapidly, with the interaction of multiple research units, biotechnology companies and 
patient groups. Several studies in the clinic are now reporting promising results with 
restoration of dystrophin expression in local muscle fibres. Future perspectives of the 
current strategies will be to overcome obstacles in the way of them becoming therapeutic 
treatments for DMD 
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